Citigroup Inc Fennec Pharmaceuticals Inc. Transaction History
Citigroup Inc
- $190 Billion
- Q1 2025
A detailed history of Citigroup Inc transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Citigroup Inc holds 17,198 shares of FENC stock, worth $139,991. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,198
Previous 18,626
7.67%
Holding current value
$139,991
Previous $117,000
11.11%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding FENC
# of Institutions
70Shares Held
13.9MCall Options Held
10KPut Options Held
83.8K-
Southpoint Capital Advisors LP New York, NY4.08MShares$33.2 Million0.72% of portfolio
-
Sonic Gp LLC Honolulu, HI2.41MShares$19.6 Million33.54% of portfolio
-
Solas Capital Management, LLC Darien, CT2.25MShares$18.3 Million9.62% of portfolio
-
Black Rock Inc. New York, NY1.19MShares$9.66 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA965KShares$7.85 Million0.0% of portfolio
About FENNEC PHARMACEUTICALS INC.
- Ticker FENC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,067,300
- Market Cap $212M
- Description
- Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...